Antiretroviral News and Research

RSS

State highlights: NYC plan for treating mentally ill; Kan. town gets abortion services again; Iowa medical marijuana

Mayor Bill de Blasio has asked several of his commissioners and aides to provide him with a plan by September to reduce the rate of incarceration among New Yorkers with mental illness. The effort, which City Hall will announce on Monday, is the administration's first major criminal justice initiative. Named the Task Force on Behavioral Health and the Criminal Justice System, it will include recommendations from the police and correction commissioners, the Manhattan district attorney, hospital administrators and judges (Goldstein, 6/1).

3 Jun 2014

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Sangamo BioSciences, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has granted a $5.6 million Strategic Partnership Award to fund clinical studies at City of Hope to develop a potentially curative ZFP Therapeutic for HIV/AIDS based on the application of Sangamo's zinc finger nuclease (ZFN) genome-editing technology in hematopoietic stem/progenitor cells (HSPCs).

31 May 2014

Longer looks: 'Abandoning' patients; commiting people with mental illness; treating PTSD

For years I had tried and failed to understand why so many of my physician colleagues persisted in ordering tests, procedures, and treatments that seemed to provide no benefit to patients and even risked harming them.

30 May 2014

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan Inc. today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets.

29 May 2014

Testing for STI co-infections may improve HIV prevention in Africa

To maximize HIV prevention efforts in South Africa and perhaps the broader region, public health officials should consider testing for other sexually transmitted infections when they test for HIV, according to a new paper in the journal Sexually Transmitted Infections.

29 May 2014

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

BioTime, Inc. today announced that it has received ISO 13485:2003 certification from BSI (British Standards Institution) for design, development, manufacture, and distribution of BioTime HyStem® hydrogels for cell delivery applications.

28 May 2014

Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Children born with HIV are far more likely to develop resistance to antiretroviral drugs than adults, according to a new Tulane University School of Medicine study.

23 May 2014

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age.

22 May 2014

Two new studies aim to change HIV infections in children, maternal deaths due to HIV

HIV has been transformed into a chronic, manageable disease for most people living with HIV in the United States, where mother-to-child transmission of HIV is now a rare occurrence.

20 May 2014

U.S. urges daily pill for those at risk of AIDS

The recommendation could transform AIDS prevention from reliance on condoms to a regimen that relies on an antiretroviral drug. Meanwhile, a report analyzes the costs and benefits of treating prison inmates for hepatitis C and a study finds that nearly half of American adults take prescriptions.

16 May 2014

Mylan releases generic version of Zyprexa Zydis Tablets

Mylan Inc. today announced that it has launched Olanzapine Orally Disintegrating Tablets (ODT), 5 mg, 10 mg, 15 mg and 20 mg, the generic version of Eli Lilly and Company's Zyprexa Zydis Tablets.

14 May 2014

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

The International Partnership for Microbicides announced today that it has received exclusive worldwide rights to a promising HIV prevention medicine called dapivirine from Janssen R&D Ireland, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

8 May 2014

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Janssen R&D Ireland Ltd. (Janssen) today announced that it has expanded its collaboration with the International Partnership for Microbicides (IPM) for the development and delivery of dapivirine (TMC120) for the prevention of HIV.

8 May 2014

Alcohol consumption linked with increased risk of advanced liver fibrosis in HIV patients

Consumption of alcohol has long been associated with an increased risk of advanced liver fibrosis, but a new study published online in Clinical Infectious Diseases from researchers at Penn Medicine and other institutions shows that association is drastically heightened in people co-infected with both HIV and chronic hepatitis C virus (HCV) infection.

5 May 2014

Johns Hopkins biochemists figure out HIV-fighting activity of enzyme

Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say.

2 May 2014

People with low cholesterol levels in immune cells experience slower HIV progression

People infected with HIV whose immune cells have low cholesterol levels experience much slower disease progression, even without medication, according to University of Pittsburgh Graduate School of Public Health research that could lead to new strategies to control infection.

29 Apr 2014

Antiretroviral News and Research

State highlights: NYC plan for treating mentally ill; Kan. town gets abortion services again; Iowa medical marijuana

CIRM grants $5.6 million to develop HIV/AIDS therapeutic using Sangamo's ZFN genome-editing technology

Longer looks: 'Abandoning' patients; commiting people with mental illness; treating PTSD

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Testing for STI co-infections may improve HIV prevention in Africa

BioTime receives ISO 13485:2003 certification for development of BioTime HyStem hydrogels

Study: Children born with HIV more likely to develop resistance to antiretroviral drugs than adults

Dolutegravir drug offers added benefit in HIV patients

Two new studies aim to change HIV infections in children, maternal deaths due to HIV

U.S. urges daily pill for those at risk of AIDS

Mylan releases generic version of Zyprexa Zydis Tablets

IPM gains exclusive worldwide rights to promising HIV prevention medicine from Janssen R&D Ireland

Janssen expands collaboration with IPM for development of dapivirine to prevent HIV

Alcohol consumption linked with increased risk of advanced liver fibrosis in HIV patients

Johns Hopkins biochemists figure out HIV-fighting activity of enzyme

People with low cholesterol levels in immune cells experience slower HIV progression

Mylan challenges FDA's decision regarding generic drug marketing exclusivity on Celecoxib Capsules

LSTM researchers to conduct extensive research on HIV and schistosomiasis coinfection in African children

Research on HIV and schistosomiasis coinfection in sub-Saharan Africa children

Community efforts boost people for HIV testing and reduce new infections

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News